Company: DNLI
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001628280-25-056361
Chunk: 29

Company: Denali Therapeutics Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 29
---
 connection with our private placement in February 2024, we granted an Investor, once that Investor was deemed an affiliate of the Company in June 2025, certain resale registration rights with respect to shares of the Company’s common stock held by the Investor under an Affiliate Registration Rights Agreement. Under the Affiliate Registration Rights Agreement, following a request by Investor, the Company is obligated to file a resale registration statement as promptly as reasonably practicable following such request, and in any event within 60 days of such request. The Company’s obligations to file such registration statement are subject to specified exceptions, and suspension and deferral rights as are set forth in the Affiliate Registration Rights Agreement. Under specified circumstances, the Company may also include securities of the Company in any such registration statement. This summary does not purport to be complete and is qualified in its entirety by the provisions of the Affiliate Registration Rights Agreement, a copy of which has been filed as an exhibit to our Form 8-K filed on June 3, 2025.

#### Listing
Our common stock is listed on the Nasdaq Global Select Market under the symbol “DNLI”.

#### Transfer Agent and Registrar
The transfer agent and registrar for our common stock is Broadridge Financial Solutions, Inc. The transfer agent and registrar’s address is 51 Mercedes Way, Edgewood, NY 11717.

<div align='center'>S-23</div>

### DESCRIPTION OF PRE-FUNDED WARRANTS
The following is a brief summary of certain terms and conditions of the pre-funded warrants being offered in this offering. The following description is subject in all respects to the provisions contained in the pre-funded warrants.

#### Form
The pre-funded warrants will be issued as individual warrant agreements to investors. The form of pre-funded warrant will be filed as an exhibit to a Current Report on Form 8-K that we expect to file with the SEC.

#### Term
The pre-funded warrants do not expire.

#### Exercisability
The pre-funded warrants are exercisable at any time on or after their original issuance. The pre-funded warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly signed exercise notice and by payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise. As an alternative to payment in immediately available funds, the holder may, in its sole discretion, elect to exercise the pre-funded warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of